ALDX vs. NATR, VSTM, VRCA, NXTC, IMNM, SPRY, GYRE, ABVX, TYRA, and IRON
Should you be buying Aldeyra Therapeutics stock or one of its competitors? The main competitors of Aldeyra Therapeutics include Nature's Sunshine Products (NATR), Verastem (VSTM), Verrica Pharmaceuticals (VRCA), NextCure (NXTC), Immunome (IMNM), ARS Pharmaceuticals (SPRY), Gyre Therapeutics (GYRE), ABIVAX Société Anonyme (ABVX), Tyra Biosciences (TYRA), and Disc Medicine (IRON). These companies are all part of the "pharmaceutical preparations" industry.
Nature's Sunshine Products (NASDAQ:NATR) and Aldeyra Therapeutics (NASDAQ:ALDX) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, community ranking, profitability, risk, institutional ownership, valuation, dividends, analyst recommendations and media sentiment.
Nature's Sunshine Products has higher revenue and earnings than Aldeyra Therapeutics. Aldeyra Therapeutics is trading at a lower price-to-earnings ratio than Nature's Sunshine Products, indicating that it is currently the more affordable of the two stocks.
Nature's Sunshine Products has a net margin of 3.69% compared to Nature's Sunshine Products' net margin of 0.00%. Aldeyra Therapeutics' return on equity of 10.59% beat Nature's Sunshine Products' return on equity.
Aldeyra Therapeutics received 319 more outperform votes than Nature's Sunshine Products when rated by MarketBeat users. Likewise, 69.26% of users gave Aldeyra Therapeutics an outperform vote while only 62.89% of users gave Nature's Sunshine Products an outperform vote.
79.4% of Nature's Sunshine Products shares are owned by institutional investors. Comparatively, 59.7% of Aldeyra Therapeutics shares are owned by institutional investors. 4.7% of Nature's Sunshine Products shares are owned by insiders. Comparatively, 8.5% of Aldeyra Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
In the previous week, Nature's Sunshine Products had 3 more articles in the media than Aldeyra Therapeutics. MarketBeat recorded 6 mentions for Nature's Sunshine Products and 3 mentions for Aldeyra Therapeutics. Aldeyra Therapeutics' average media sentiment score of 1.24 beat Nature's Sunshine Products' score of 0.14 indicating that Nature's Sunshine Products is being referred to more favorably in the media.
Nature's Sunshine Products presently has a consensus target price of $24.00, suggesting a potential upside of 56.66%. Aldeyra Therapeutics has a consensus target price of $9.33, suggesting a potential upside of 141.80%. Given Nature's Sunshine Products' higher possible upside, analysts clearly believe Aldeyra Therapeutics is more favorable than Nature's Sunshine Products.
Nature's Sunshine Products has a beta of 0.85, meaning that its stock price is 15% less volatile than the S&P 500. Comparatively, Aldeyra Therapeutics has a beta of 1.45, meaning that its stock price is 45% more volatile than the S&P 500.
Summary
Nature's Sunshine Products beats Aldeyra Therapeutics on 10 of the 16 factors compared between the two stocks.
Get Aldeyra Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for ALDX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ALDX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Aldeyra Therapeutics Competitors List
Related Companies and Tools
